Peer Reviewed
Perspectives

New Australian indication for cardiovascular disease prevention with statin therapy

Ian Hamilton-craig
Abstract
The new JUPITER-based TGA indication in Australia for rosuvastatin therapy is for the prevention of major cardiovascular events in men aged 50 years and older and women aged 60 years and older with no clinically-evident cardiovascular disease but who have at least two conventional risk factors.
Key Points
  • The results of the JUPITER trial have led to approval in Australia of a new indication for rosuvastatin therapy, broadening the range of people for whom statin therapy is indicated.
  • The new TGA indication approves rosuvastatin therapy for the prevention of major cardiovascular disease (CVD) events in men aged 50 years and older and women aged 60 years and older with no clinically-evident CVD who have at least two conventional risk factors.
  • The new indication broadens current PBS criteria and provides a greater opportunity for the primary prevention of CVD.
  • The new indication does not include measurement of high-sensitivity C-reactive protein.
Purchase the PDF version of this article
Purchase PDF AUD$34.99
Subscribe for full access to all articles
Already a subscriber?